RGX-202 BLA for DMD on track for Q3 submission, with rabies virus data Showing durable efficacy
REGENXBIO reported strong second-quarter results, announcing the initiation of RGX-202 BLA filing and up to ~2H 2027 catalyst expectations, extending its cash runway consistent with its gene therapy pipeline development progress.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day